Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05314608 · ClinicalTrials.gov registry record

Knee Related Subchondral Bone Lesions Treated With IOBP

A clinical trial of Subchondral Cyst, sponsored by Arthrex.

Recruiting
Registry status
100
Enrollment target
5
Study locations

NCT05314608 is a study of Subchondral Cyst that is actively recruiting participants, run by Arthrex. The registered enrollment target is 100 participants. The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05314608, a study of Subchondral Cyst, is actively recruiting participants, sponsored by Arthrex.

RECRUITING
Registry status
100 participants
Enrollment target
5
Study locations

Study Summary

The study will be a prospective, multicenter clinical study evaluating clinical and patient reported outcome measures of subjects receiving IOBP® surgical technique using Angel cPRP and BMA processing system to treat subchondral bone pathology (SBP).

Conditions Studied

Interventions

  • COMBINATION_PRODUCT IntraOsseous BioPlasty® (IOBP®) Surgical Technique into the knee

Study Locations (5)

Colorado

  • University of Colorado Sports Medicine - Denver

Florida

  • Andrews Research and Education Foundation - Gulf Breeze

Maryland

  • TidalHealth Peninsula Regional, Inc. - Salisbury

Ohio

  • The Ohio State University - Columbus

Pennsylvania

  • Allegheny-Singer Research Institute - Pittsburgh

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2021-11-17
Est. Completion 2027-05-17

Sponsor

Arthrex

12 total trials

What the Registry Record Tells You About NCT05314608

The ClinicalTrials.gov registry entry for NCT05314608 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arthrex, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Subchondral Cyst appearing as the primary indexed condition, and to 1 intervention - of which IntraOsseous BioPlasty® (IOBP®) Surgical Technique into the knee is the first listed.

NCT05314608 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Colorado, Florida, Maryland.

Frequently Asked Questions

What is clinical trial NCT05314608 about?

NCT05314608 is a clinical study titled "Knee Related Subchondral Bone Lesions Treated With IOBP". The study will be a prospective, multicenter clinical study evaluating clinical and patient reported outcome measures of subjects receiving IOBP® surgical technique using Angel cPRP and BMA processing system to treat subchondral bone pathology (SBP).

What is the current status of trial NCT05314608?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2021-11-17. Estimated completion is 2027-05-17.

What conditions does trial NCT05314608 study?

This clinical trial studies the following conditions: Subchondral Cyst.

What interventions are being tested in trial NCT05314608?

The interventions under investigation include: IntraOsseous BioPlasty® (IOBP®) Surgical Technique into the knee (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT05314608?

This trial is sponsored by Arthrex, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05314608 being conducted?

This trial has 5 study locations across Colorado, Florida, Maryland, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.